Literature DB >> 33770264

Perioperative outcomes and survival in elderly patients aged ≥ 75 years undergoing gastrectomy for gastric cancer: an 18-year retrospective analysis in a single Western centre.

Elinor Tan1,2,3, Susanna Lam4,5, Shew Phyo Han4, David Storey4,5,6, Charbel Sandroussi4,5,6.   

Abstract

PURPOSE: Surgical resection for elderly patients with gastric cancer is controversial. This study aims to evaluate the preoperative features and postoperative short- and long-term outcomes of elderly patients following surgical resection for gastric adenocarcinoma.
METHODS: Between January 2000 and May 2018, a total of 177 consecutive patients underwent curative gastrectomy for gastric adenocarcinoma was retrospectively reviewed. Propensity score matching (PSM) analysis was used to balance confounding covariates between the elderly and non-elderly groups. Clinicopathological characteristics, intraoperative characteristics, postoperative complications and long-term survival outcomes including overall survival (OS) and Disease Specific Survival (DSS) were compared and analysed using the Kaplan-Meier log-rank test. Multivariate cox proportional hazards regression analysis of clinicopathological factors influencing survival were evaluated.
RESULTS: There were 50 patients in the elderly group (age ≥ 75 years) and 127 patients in the non-elderly group (age < 75 years). Elderly patients had more comorbid conditions (p < 0.001), lower albumin concentration (p = 0.034), lower haemoglobin levels (p = 0.001), and poorer renal function (p = 0.043). TNM stage was similar between both groups (p = 0.174); however, lymphatic invasion (p = 0.006) and lymph node metastasis (p = 0.029) were higher in the elderly group. Elderly patients were much less likely to receive any chemo- (p < 0.001) or radiotherapy treatment (p = 0.007) with surgical treatment. After PSM, there were 50 patients in each group. Elderly patients were more likely to develop complications (Clavien Dindo ≥ 2: 50% vs. 26%, p = 0.003). The most common postoperative complications were pneumonia (12% vs. 6%, p = 0.498) and delirium (10% vs. 0%, p = 0.066). Elderly patients had a longer median length of hospital stay (median (IQR): 15.6(9.5) vs. 11.3 (9.9), p = 0.030). There were no differences in 30-day mortality (elderly vs. non-elderly: 1% vs. 1%, p = 0.988). Before and after PSM, age remains an independent predictor of postoperative complications. Before PSM, the estimated mean OS for the elderly and non-elderly patients were 108 months (95%CI, 72.5-143.5) and 143 months (95%CI, 123.0-163.8), respectively (p = 0.264). After PSM, the estimated mean OS for the elderly and non-elderly patients were 108 months (95%CI, 72.5-143.5) and 140 months (95%CI, 112.1-168.2), respectively, (p = 0.360). Before PSM, the estimated mean DSS for the elderly and non-elderly patients were 94 months (95%CI, 61.9-127.5) and 121 months (95%CI, 100.9-141.0), respectively (p = 0.405). After PSM, the estimated mean DSS for the elderly and non-elderly patients were 94 months (95%CI, 61.9-127.5) and 115 months (95%CI, 87.3-143.3), respectively (p = 0.721). Age was not an independent predictor of mortality following gastrectomy for gastric cancer in both PSM matched and unmatched cohort.
CONCLUSION: Chronological age alone is not a contraindication to curative resection of gastric adenocarcinoma in elderly patients with acceptable risk. Whilst age affects perioperative complications, the incidence of postoperative mortality and overall survival were not significantly different between elderly and non-elderly gastric cancer patients treated with curative surgery. Gastrectomy with D2 lymphadenectomy can also be performed in carefully selected elderly patients by surgeons with expertise in gastric resection along with appropriate perioperative management.

Entities:  

Keywords:  Elderly; Gastrectomy; Gastric adenocarcinoma; Morbidity; Survival

Year:  2021        PMID: 33770264     DOI: 10.1007/s00423-021-02116-w

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  43 in total

1.  Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel.

Authors:  Nils Homann; Claudia Pauligk; Kim Luley; Thomas Werner Kraus; Hans-Peter Bruch; Akin Atmaca; Frank Noack; Hans-Michael Altmannsberger; Elke Jäger; Salah-Eddin Al-Batran
Journal:  Int J Cancer       Date:  2011-08-05       Impact factor: 7.396

2.  Predictors of operative morbidity and mortality in gastric cancer surgery.

Authors:  D J Park; H-J Lee; H-H Kim; H-K Yang; K U Lee; K J Choe
Journal:  Br J Surg       Date:  2005-09       Impact factor: 6.939

3.  Characteristics and prognosis of gastric cancer in patients aged ≥ 70 years.

Authors:  Yue-Xiang Liang; Jing-Yu Deng; Han-Han Guo; Xue-Wei Ding; Xiao-Na Wang; Bao-Gui Wang; Li Zhang; Han Liang
Journal:  World J Gastroenterol       Date:  2013-10-21       Impact factor: 5.742

4.  Gastric cancer surgery in elderly patients.

Authors:  Stephen Gretschel; Lope Estevez-Schwarz; Michael Hünerbein; Ulrike Schneider; Peter M Schlag
Journal:  World J Surg       Date:  2006-08       Impact factor: 3.352

5.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.

Authors:  J S Macdonald; S R Smalley; J Benedetti; S A Hundahl; N C Estes; G N Stemmermann; D G Haller; J A Ajani; L L Gunderson; J M Jessup; J A Martenson
Journal:  N Engl J Med       Date:  2001-09-06       Impact factor: 91.245

Review 6.  Gastric adenocarcinoma: review and considerations for future directions.

Authors:  Bryan J Dicken; David L Bigam; Carol Cass; John R Mackey; Anil A Joy; Stewart M Hamilton
Journal:  Ann Surg       Date:  2005-01       Impact factor: 12.969

7.  Surgical outcomes for patients aged 80 and older: morbidity and mortality from major noncardiac surgery.

Authors:  Mary Beth Hamel; William G Henderson; Shukri F Khuri; Jennifer Daley
Journal:  J Am Geriatr Soc       Date:  2005-03       Impact factor: 5.562

8.  Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.

Authors:  Shinichi Sakuramoto; Mitsuru Sasako; Toshiharu Yamaguchi; Taira Kinoshita; Masashi Fujii; Atsushi Nashimoto; Hiroshi Furukawa; Toshifusa Nakajima; Yasuo Ohashi; Hiroshi Imamura; Masayuki Higashino; Yoshitaka Yamamura; Akira Kurita; Kuniyoshi Arai
Journal:  N Engl J Med       Date:  2007-11-01       Impact factor: 91.245

9.  Outcome of gastric cancer in the elderly: a population-based evaluation of the Munich Cancer Registry.

Authors:  Anne Schlesinger-Raab; André L Mihaljevic; Silvia Egert; Rebecca Emeny; Karl-Walter Jauch; Jörg Kleeff; Alexander Novotny; Natascha C Nüssler; Miriam Rottmann; Wolfgang Schepp; Wolfgang Schmitt; Gabriele Schubert-Fritschle; Bernhard Weber; Christoph Schuhmacher; Jutta Engel
Journal:  Gastric Cancer       Date:  2015-08-11       Impact factor: 7.370

10.  Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer.

Authors:  S Lorenzen; C Pauligk; N Homann; H Schmalenberg; E Jäger; S-E Al-Batran
Journal:  Br J Cancer       Date:  2013-01-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.